Eton Pharmaceuticals (ETON) Total Non-Current Liabilities (2017 - 2025)

Eton Pharmaceuticals has disclosed Total Non-Current Liabilities across 5 years of filings, most recently posting $60.7 million for Q4 2025.

• Total Non-Current Liabilities for Q4 2025 came in at $60.7 million, up 21.77% year-over-year; the trailing twelve-month figure through Dec 2025 was $60.7 million (up 21.77% YoY), and the FY2025 annual result was $60.7 million, up 21.77% from the prior year.
• Total Non-Current Liabilities came in at $60.7 million for Q4 2025 at Eton Pharmaceuticals, down from $77.4 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $77.4 million in Q3 2025 to a low of $16.3 million in Q4 2023.
• The 3-year median for Total Non-Current Liabilities is $58.1 million (2025), against an average of $55.5 million.
• Across the five-year window, Total Non-Current Liabilities surged 206.62% in 2024 and climbed 21.77% in 2025, its largest moves.
• Eton Pharmaceuticals' Total Non-Current Liabilities stood at $16.3 million in 2023, then soared by 206.62% to $49.9 million in 2024, then advanced by 21.77% to $60.7 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $60.7 million (Q4 2025), $77.4 million (Q3 2025), and $73.4 million (Q2 2025), per Business Quant data.